Literature DB >> 18379008

Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia.

Frank J T Staal1, Anton W Langerak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18379008     DOI： 10.3324/haematol.12917

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.

Authors:  Jixin Ding; Melissa L Fishel; April M Reed; Erin McAdams; Magdalena B Czader; Angelo A Cardoso; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2017-04-26       Impact factor: 6.261

Review 2.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

3.  Molecular basis for the tissue specificity of β-catenin oncogenesis.

Authors:  A Sharma; J M Sen
Journal:  Oncogene       Date:  2012-06-11       Impact factor: 9.867

4.  Temporal regulation of Wnt/β-catenin signaling is important for invariant NKT cell development and terminal maturation.

Authors:  Kalyani Pyaram; Jyoti Misra Sen; Cheong-Hee Chang
Journal:  Mol Immunol       Date:  2017-02-14       Impact factor: 4.407

Review 5.  Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Authors:  Yulia Nefedova; Dmitry Gabrilovich
Journal:  Drug Resist Updat       Date:  2008-10-31       Impact factor: 18.500

6.  Gamma-secretase inhibitors: Notch so bad.

Authors:  Gerard C Grosveld
Journal:  Nat Med       Date:  2009-01       Impact factor: 53.440

7.  A phase II study of RO4929097 in metastatic colorectal cancer.

Authors:  Jonathan R Strosberg; Timothy Yeatman; Jill Weber; Domenico Coppola; Michael J Schell; Gang Han; Khaldoun Almhanna; Richard Kim; Tiffany Valone; Helen Jump; Dan Sullivan
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

8.  A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

Authors:  Noelle K LoConte; Albiruni R A Razak; Percy Ivy; Amye Tevaarwerk; Rachael Leverence; Jill Kolesar; Lillian Siu; Sam J Lubner; Daniel L Mulkerin; William R Schelman; Dustin A Deming; Kyle D Holen; Lakeesha Carmichael; Jens Eickhoff; Glenn Liu
Journal:  Invest New Drugs       Date:  2014-10-17       Impact factor: 3.850

9.  Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.

Authors:  P A Candy; M R Phillips; A D Redfern; S M Colley; J A Davidson; L M Stuart; B A Wood; N Zeps; P J Leedman
Journal:  Br J Cancer       Date:  2013-07-30       Impact factor: 7.640

10.  Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.

Authors:  Edward Pan; Jeffrey G Supko; Thomas J Kaley; Nicholas A Butowski; Timothy Cloughesy; Jinkyu Jung; Serena Desideri; Stuart Grossman; Xiaobu Ye; Deric M Park
Journal:  J Neurooncol       Date:  2016-11-08       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.